February 16th 2024
The FDA has granted an orphan drug designation to tigilanol tiglate for the treatment of soft tissue sarcoma.
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Immunotherapy and Chemotherapy Trial Arm for Sarcoma Commences
September 24th 2015A sarcoma study arm of the phase II portion of the multiarm PembroPlus clinical trial that combines immunotherapy with chemotherapy has commenced at Cancer Treatment Centers of America (CTCA), Western Regional Medical Center, Goodyear, Arizona
Read More
Study Shows First-Time Survival Benefit for Soft Tissue Sarcoma
June 2nd 2015Marking the first time a phase III study has shown a survival advantage for patients with soft tissue sarcoma, treatment with eribulin (Halaven) demonstrated improved overall survival (OS) by 2 months compared with dacarbazine in patients with advanced leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).
Read More
Brian A. Van Tine, MD, PhD, assistant professor, Washington University School of Medicine in St. Louis, discusses the SARC021 trial, which examined TH-302 in combination with doxorubicin versus doxorubicin alone to treat patients with locally advanced unresectable or metastatic soft tissue sarcoma.
Watch
AR Findings Highlight Detailed Tumor-Profiling Study
March 7th 2014A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression.
Read More
Phase I/II Data Shows Belinostat Could Provide Benefit for Patients in STS
November 27th 2013Belinostat (PXD101), in combination with doxorubicin, could provide benefit for patients with soft tissue sarcomas, according to final results from the first stage of the phase II portion of the phase I/II CLN-14 clinical trial.
Read More
Aldoxorubicin Demonstrates Benefit in Phase IIb Trial in Soft Tissue Sarcomas
November 22nd 2013Aldoxorubicin demonstrated response rates that culminated in a higher incidence of stable disease versus doxorubicin as a first-line treatment for advanced soft tissue sarcomas, according to results from an ongoing phase IIb study.
Read More
Novel Agents Under Investigation for the Treatment of GIST
November 21st 2013Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses novel agents that are currently under investigation for the treatment of gastrointestinal stromal tumors
Watch